Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

CYLD (human) polyclonal antibody

 
BML-PW0760-0025 25 µl 108.00 USD
 
BML-PW0760-0100 100 µl 356.00 USD
Do you need bulk/larger quantities?
 

Product Specification

Alternative Name:Probable ubiquitin carboxyl-terminal hydrolase CYLD
 
Host:Rabbit
 
Immunogen:Synthetic peptide corresponding to aa 336-353 of human CYLD.
 
UniProt ID:Q9NQC7
 
Species reactivity:Human
 
Applications:WB
 
Recommended Dilutions/Conditions:Western Blot (1:1,000)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application.
 
Purity Detail:Purified by salt precipitation.
 
Formulation:Liquid. In PBS containing 0.01% sodium azide.
 
Use/Stability:Stable for at least 1 year after receipt when stored at -20°C. Dilute with PBS, pH 7.2-7.4, containing 1% normal goat serum (if a goat anti-rabbit IgG linker antibody is to be used). Store diluted antibody at +4°C, do not freeze and use within 1 month.
 
Handling:Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C.
 
Shipping:Shipped on Blue Ice
 
Short Term Storage:-20°C
 
Long Term Storage:-20°C
 
Scientific Background:The tumor suppressor CYLD is a deubiquitinylating enzyme (DUB) that antagonises NF-κB and JNK signaling by disassembly of Lys63-linked ubiquitin chains synthesised in response to cytokine stimulation. The DUB activity of CYLD is mediated by its C-terminal ubiquitin specific protease (USP) domain, pathogenic truncations and mutations of which are associated with the hypertrophic skin tumor cylindromatosis through disruption of the USP domain and subsequent loss of CYLD catalytic activity.
 
bml-pw0760 wb
Figure: Detection of CYLD in HeLa S100 cytosolic fraction (Prod. No. BML-SW8750, 10µg) by Western blotting using PAb to CYLD (human) (Prod. No. BML-PW0760) at 1:5000 dilution.
Please mouse over
bml-pw0760 wb

Product Literature References

TRAF-interacting protein (TRIP) negatively regulates the TNF receptor-associated factor 2 (TRAF2) ubiquitin-dependent pathway by suppressing the TRAF2 - sphingosine-1-phosphate (S1P) interaction: E.S. Park, et al.; J. Biol. Chem. 290, 9660 (2015), Abstract; Full Text

General Literature References

Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains: D. Komander, et al.; EMBO Rep. 10, 466 (2009), Abstract;
The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module: D. Komander, et al.; Mol. Cell 29, 451 (2008), Abstract;
Deubiquitinating enzyme CYLD regulates the peripheral development and naive phenotype maintenance of B cells: W. Jin, et al.; J. Biol. Chem. 282, 15884 (2007), Abstract; Full Text
CYLD in ubiquitin signaling and tumor pathogenesis: F. Ikeda & I. Dikic; Cell 125, 643 (2006), Abstract;
CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members: E. Trompouki, et al.; Nature 424, 793 (2003), Abstract;
Identification of the familial cylindromatosis tumour-suppressor gene: G.R. Bignell, et al.; Nat. Genet. 25, 160 (2000), Abstract;

Related Literature

Brochures
Stem Cells
Stem Cells
Download as PDF

Catalogs
Ubiquitin & UBL Signaling Catalog
Ubiquitin & UBL Signaling Catalog
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,